Pharming Group (OTCMKTS:PHGUF – Get Free Report) is anticipated to post its results before the market opens on Thursday, March 12th. Analysts expect Pharming Group to post earnings of $0.0015 per share and revenue of $89.7220 million for the quarter.
Pharming Group Stock Down 11.2%
PHGUF stock opened at $1.51 on Tuesday. Pharming Group has a 1-year low of $0.79 and a 1-year high of $2.17. The company has a current ratio of 3.16, a quick ratio of 2.39 and a debt-to-equity ratio of 0.46. The business’s 50-day moving average price is $1.78 and its two-hundred day moving average price is $1.61.
Pharming Group Company Profile
Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.
Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.
Recommended Stories
- Five stocks we like better than Pharming Group
- Buy this Gold Stock Before May 15th, 2026
- America’s 1776 happening again
- J.P. Morgan is betting on this coin
- Central banks just did something they haven’t done since 1967
- My Epstein Story
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
